FDA Sings Paeans To Postmarket Vigilance: “Lower Cost,” Quicker Approvals
This article was originally published in The Gray Sheet
Executive Summary
FDA's plan to hire a new chief economist is consistent with Commissioner Mark McClellan's pledge to evaluate the agency's cost efficiency as a top priority of his tenure
You may also be interested in...
MCAC Likely Will Assess Potential Postmarket Surveillance Of LVADs
CMS expects the Medicare Coverage Advisory Committee to consider recommending postmarket registries of left-ventricular assist devices as a condition of national coverage
MCAC Likely Will Assess Potential Postmarket Surveillance Of LVADs
CMS expects the Medicare Coverage Advisory Committee to consider recommending postmarket registries of left-ventricular assist devices as a condition of national coverage
MeDSuN Voluntary Reporting Shines Light On Potential Device Concern
FDA's Medical Device Surveillance Network (MeDSuN) recently alerted FDA to a problem with a certain line of angiocatheter guidewires, demonstrating the ability of the system to identify potential device concerns, staffers note